Bispecific antibodies(bsAb) are artificial antibodies containing two specific antigen binding sites, and their novel mechanism of action(MOA) has been shown better efficacy and higher safety compared to monoclonal antibodies. Based on clinical results, bsAb has shown better therapeutic efficacy compared with combination treatment. Here is the workflow of the bispecific antibody discovery servic
e process.